/
COGT
$38.21+$0.11 (+0.29%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.5B
171M shares
52-week range
$7.07 – $43.73
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$30.10
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $22.5M | $7.9M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $43.7K | $25.7M | $0 | $0 | $0 | $0 | $4.6M |
| Gross profit | $9.7M | $22.5M | −$17.9M | $0 | $0 | $0 | $0 | −$4.6M |
| Gross margin | 100.0% | 99.8% | -227.0% | — | — | — | — | — |
| R&D | $38.3M | $43.7M | $72.6M | $55.9M | $121.6M | $173.8M | $232.7M | $269.8M |
| Operating income | −$36.0M | −$32.2M | −$82.2M | −$75.6M | −$147.8M | −$208.1M | −$275.9M | −$333.4M |
| EBITDA | −$34.7M | −$30.9M | −$34.6M | −$70.3M | −$130.4M | −$188.8M | −$251.5M | −$321.3M |
| Net income | −$34.5M | −$30.3M | −$74.8M | −$72.3M | −$140.2M | −$192.4M | −$255.9M | −$328.9M |
| Net margin | -354.8% | -134.6% | -950.4% | — | — | — | — | — |
| EPS (diluted) | -5.55 | -3.97 | -6.00 | -1.85 | -2.26 | -2.42 | -2.46 | -2.55 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-2.25 | $-2.68–$-2.04 | 9 |
| 2027 | $345M | $-0.78 | $-1.45–$0.21 | 8 |
| 2028 | $730M | $0.77 | $-0.35–$2.98 | 10 |
| 2029 | $1.3B | $2.73 | $0.41–$6.73 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.74
Price
$38.21
Implied downside
-98%
Peer comparison
Cogent Biosciences, Inc. Common Stock
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
www.cogentbio.com- Employees
- 258
- IPO / List date
- Mar 29, 2018
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds COGT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 706,268 | $27.2M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-11-09 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded COGT yet.
